New Muramyl Dipeptide (MDP) Mimics Without the Carbohydrate Moiety As Potential Adjuvant Candidates for a Therapeutic Hepatitis B Vaccine (HBV)

Nan Zhao,Yao Ma,Shengmei Zhang,Xin Fang,Zhenglun Liang,Gang Liu
DOI: https://doi.org/10.1016/j.bmcl.2011.05.056
IF: 2.94
2011-01-01
Bioorganic & Medicinal Chemistry Letters
Abstract:A series of new muramyl dipeptide (MDP) mimics were designed and synthesized via a solid-phase synthetic route. Their adjuvant activities were evaluated ex vivo for investigation of the synergism of the S(28-39) peptide, which is an MHC class I binding epitope of recombinant hepatitis B surface antigen (HBsAg) for both humans and mice. Several compounds without the carbohydrate moiety exerted better adjuvanticity than the MDP-C that has been reported by our laboratory previously. A primary screening test revealed that compounds 6, 14 and 16 exhibited stronger adjuvanticity compared with other MDP mimics.
What problem does this paper attempt to address?